AQR Arbitrage LLC Sells 74,853 Shares of Abrdn Life Sciences Investors (NYSE:HQL)

AQR Arbitrage LLC lessened its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 28.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 188,425 shares of the company's stock after selling 74,853 shares during the period. AQR Arbitrage LLC owned approximately 0.69% of Abrdn Life Sciences Investors worth $2,472,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. BankPlus Trust Department bought a new stake in shares of Abrdn Life Sciences Investors in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Abrdn Life Sciences Investors by 379.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock worth $64,000 after acquiring an additional 3,847 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Abrdn Life Sciences Investors during the fourth quarter worth $154,000. Kingswood Wealth Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the fourth quarter valued at $160,000. Finally, Kapstone Financial Advisors LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 11.0% during the fourth quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company's stock valued at $185,000 after purchasing an additional 1,300 shares during the last quarter. 32.21% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Saba Capital Management, L.P. sold 36,536 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $13.75, for a total value of $502,370.00. Following the transaction, the insider now directly owns 3,276,181 shares of the company's stock, valued at approximately $45,047,488.75. This trade represents a 1.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 251,959 shares of company stock worth $3,205,206. 10.06% of the stock is owned by company insiders.

Abrdn Life Sciences Investors Stock Up 0.2 %

Shares of HQL stock traded up $0.02 during trading hours on Monday, reaching $13.03. 71,554 shares of the stock traded hands, compared to its average volume of 101,747. The business has a fifty day moving average price of $12.48 and a 200 day moving average price of $13.50. Abrdn Life Sciences Investors has a 1-year low of $10.55 and a 1-year high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 14.43%. The ex-dividend date was Friday, February 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.